A UCLA club is partnering with local senior living homes and engaging in research to raise awareness about Alzheimer’s disease and dementia.

Brain-Health Education and Advocacy Movement at UCLA works with the Mary S. Easton Center for Alzheimer’s Research and Care at UCLA, which allows club members to learn from medical professionals and give back to the community, said Charlize Yip, BEAM’s current education director and incoming president.

Yip, a third-year physiological science student, added that BEAM allows students to shadow remote support groups for caregivers.

“A big part of healthcare is the caregivers who are involved, especially when it comes to Alzheimer’s and dementia,” she said. “It was always a really good experience to see the caregiver’s perspective, and then really understand what they’re going through and how – even though they don’t have the disease – they are heavily impacted.”

Read more HERE

The U.S. Food and Drug Administration today approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat agitation associated with dementia due to Alzheimer’s disease in adults. The drug is the first FDA-approved treatment for this condition that is not an antipsychotic. FDA initially approved Auvelity in 2022 to treat major depressive disorder in adults.

Read more HERE

While Alzheimer’s disease is commonly associated with older adults, it can also affect people under the age of 65. This form is known as early-onset Alzheimer’s disease, and in some cases it may develop in individuals in their 30s, 40s, or 50s.

Read more HERE

Having an optimistic outlook on life may be good for your brain, according to a new report. The study found that older adults who looked on the bright side of life were less likely to develop Alzheimer’s disease and other forms of dementia as they aged.

Read more HERE

Glial-to-neuron conversion therapy decreases inflammation and restores the brain-blood barrier in Alzheimer’s disease model macaques.

In search of an innovative medicine, a group of scientists at Jinan University in Guangdong, China, has developed a disease-modifying therapy that, when tested in a non-human primate Alzheimer’s model, has shown improvements in both biological markers and clinical aspects of the disease. “These outcomes offer new hope for the tens of millions of Alzheimer’s patients worldwide,” says Wenliang Lei, principal investigator at Guangdong-Hong Kong-Macau Institute of CNS Regeneration (GHMICR) in Jinan University, and co-corresponding author of the study published in Advanced Science.

Read more HERE